tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Chemomab Therapeutics Ltd

CMMB
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
1.660USD
-0.040-2.35%
์ข…๊ฐ€ย 05/15, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
47.76M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Chemomab Therapeutics Ltd ํšŒ์‚ฌ

Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Chemomab Therapeutics Ltd ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ CMMB
ํšŒ์‚ฌ ์ด๋ฆ„Chemomab Therapeutics Ltd
์ƒ์žฅ์ผAug 14, 2012
CEOMor (Adi)
์ง์› ์ˆ˜16
์œ ํ˜•Depository Receipt
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒAug 14
์ฃผ์†ŒKiryat Atidim, Building 7
๋„์‹œTEL AVIV-YAFO
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€Israel
์šฐํŽธ ๋ฒˆํ˜ธ6158002
์ „ํ™”972773310156
์›น์‚ฌ์ดํŠธhttps://www.chemomab.com/
์ข…๋ชฉ ์ฝ”๋“œ CMMB
์ƒ์žฅ์ผAug 14, 2012
CEOMor (Adi)

Chemomab Therapeutics Ltd์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-487.01%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-487.01%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, May 14
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, May 14
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Otto (Erik)
5.35%
Apeiron Investment Group Ltd
3.93%
Rivendell Investments 2017-9 LLC
3.85%
Citadel Advisors LLC
1.44%
Adar1 Capital Management LLC
1.11%
๊ธฐํƒ€
84.32%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Otto (Erik)
5.35%
Apeiron Investment Group Ltd
3.93%
Rivendell Investments 2017-9 LLC
3.85%
Citadel Advisors LLC
1.44%
Adar1 Capital Management LLC
1.11%
๊ธฐํƒ€
84.32%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Individual Investor
7.65%
Family Office
3.93%
Corporation
3.85%
Hedge Fund
3.27%
Investment Advisor
1.42%
Research Firm
0.53%
Venture Capital
0.26%
Investment Advisor/Hedge Fund
0.11%
๊ธฐํƒ€
78.98%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Apr 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Apr 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2026Q1
33
402.96K
5.60%
-450.97K
2025Q4
30
390.31K
17.98%
--
2025Q3
30
390.31K
17.98%
-667.39K
2025Q2
30
1.06M
18.61%
+124.78K
2025Q1
31
932.92K
24.29%
-212.50K
2024Q4
32
1.04M
26.27%
-97.26K
2024Q3
29
1.14M
22.64%
+165.56K
2024Q2
28
668.24K
21.48%
+2.79K
2024Q1
32
666.14K
22.68%
-139.12K
2023Q4
33
705.36K
20.90%
+69.50K
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Otto (Erik)
385.00K
5.35%
-37.50K
-8.88%
Feb 10, 2026
Apeiron Investment Group Ltd
283.00K
3.93%
+101.21K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
277.13K
3.85%
--
--
Dec 31, 2025
Citadel Advisors LLC
103.78K
1.44%
+103.78K
--
Dec 31, 2025
Adar1 Capital Management LLC
80.00K
1.11%
+80.00K
--
Dec 31, 2025
Mor George (Adi)
79.27K
1.1%
--
--
Dec 31, 2024
Kestra Private Wealth Services, LLC
51.71K
0.72%
+51.71K
--
Dec 31, 2025
Ikarian Capital LLC
51.79K
0.72%
-1.47K
-2.76%
Dec 31, 2025
George (Kobi)
50.06K
0.7%
-12.73K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
35.30K
0.49%
-2.50K
-6.61%
Dec 31, 2024
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
์ด๋ฆ„
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
Aug 08, 2025
Merger
4โ†’1
Mar 16, 2021
Merger
16โ†’1
Mar 16, 2021
Merger
16โ†’1
Mar 16, 2021
Merger
16โ†’1
Mar 16, 2021
Merger
16โ†’1
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
Aug 08, 2025
Merger
4โ†’1
Mar 16, 2021
Merger
16โ†’1
Mar 16, 2021
Merger
16โ†’1
Mar 16, 2021
Merger
16โ†’1
Mar 16, 2021
Merger
16โ†’1
KeyAI
๎™